---
title: "Thymosin β4 (Tβ4)"
canonical_url: https://peptidelibrary.app/library/thymosin-beta-4
description: "43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Thymosin β4 (Tβ4)

Thymosin β4 (Tβ4), also called Timbetasin or Full-length thymosin beta-4, is an actin-sequestering peptide in the Wound Healing / Cytoprotective class. Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton.

43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.

Also known as: Timbetasin, Full-length thymosin beta-4, Thymosin Alpha-4.

Categories: Muscle/Recovery, Cosmetic, Experimental.

## Classification

- Type: Actin-sequestering peptide / research
- Mechanism class: Wound Healing / Cytoprotective
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton. That function underlies its effects on cell motility, since directed migration requires rapid local actin polymerisation. Beyond actin binding it has been reported to promote angiogenesis, upregulate laminin-5, downregulate inflammatory cytokines, and reduce apoptosis in injured tissue. It has been investigated in dermal, corneal and cardiac repair. It is not approved for any use and is prohibited in sport.

Targets: G-actin.

Origin: Endogenous 43-aa peptide; synthetic research material.

## Properties

- Molecular formula: C212H350N56O78S
- Molecular weight: ≈4963 g/mol
- CAS number: 77591-33-4
- Half-life: Not well established in humans

## Evidence

- Evidence level: Clinical Trial Evidence
- Highest documented: Controlled human trials
- Human trials: 3
- Controlled human trials: 3
- Preclinical sources: 0
- Latest source: 2010

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. 2010. Controlled human trial. Population: Healthy volunteers (4 cohorts of 10). Well tolerated, with no dose-limiting toxicity; safety and pharmacokinetics only [Source](https://pubmed.ncbi.nlm.nih.gov/20536472/)
2. NCT00832091 — Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers. Controlled human trial. Population: Adults with venous stasis ulcers (n=72). Safety comparable to placebo; the authors suggested 0.03% may speed healing [Source](https://clinicaltrials.gov/study/NCT00832091)
3. NCT02974907 — Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-2. Controlled human trial. Population: Adults with dry eye syndrome (n=601). Results are posted on ClinicalTrials.gov and not summarised here [Source](https://clinicaltrials.gov/study/NCT02974907)

### Registered trials

- [NCT00832091](https://clinicaltrials.gov/study/NCT00832091)
- [NCT02974907](https://clinicaltrials.gov/study/NCT02974907)

## Safety

Side effects: Limited human AE data for research vials.

Risks: WADA / non-approved substance risk.

Human safety basis: Clinical trial reports

Key limitations: No established human dosage.; Not approved by the FDA for any use..

## Regulatory status

Thymosin β4 (Tβ4) is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Thymosin β4 (Tβ4)?

43-aa G-actin-sequestering peptide studied for wound healing and cardiac repair (timbetasin programs). Not FDA-approved. Distinct from the shorter TB-500 fragment.

### How does Thymosin β4 (Tβ4) work?

Thymosin beta-4 is a 43-amino-acid peptide and the principal G-actin sequestering protein in most mammalian cells, binding monomeric actin through its LKKTETQ motif and maintaining the unpolymerised pool that cells draw on to remodel their cytoskeleton. That function underlies its effects on cell motility, since directed migration requires rapid local actin polymerisation.

### Is Thymosin β4 (Tβ4) FDA approved?

No. Thymosin β4 (Tβ4) is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Thymosin β4 (Tβ4)?

Reported half-life for Thymosin β4 (Tβ4) is Not well established in humans. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Thymosin β4 (Tβ4) banned in sport?

Thymosin β4 (Tβ4) is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Thymosin β4 (Tβ4)?

Compounds most often compared with Thymosin β4 (Tβ4) include BPC-157, TB-500 (Thymosin Beta-4 fragment), Pentadeca Arginate and GHK-Cu (Copper Peptide). They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Thymosin beta 4: An emerging therapeutic candidate for kidney diseases — Peptides, 2026](https://pubmed.ncbi.nlm.nih.gov/41570941/)
- [Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system? — Can J Physiol Pharmacol, 2019](https://pubmed.ncbi.nlm.nih.gov/30854877/)
- [Thymosin beta 4 and the eye: the journey from bench to bedside — Expert Opin Biol Ther, 2018](https://pubmed.ncbi.nlm.nih.gov/30063853/)
- [Thymosin β4-mediated protective effects in the heart — Expert Opin Biol Ther, 2018](https://pubmed.ncbi.nlm.nih.gov/30063857/)
- [Cardioprotection by Thymosin Beta 4 — Vitam Horm, 2016](https://pubmed.ncbi.nlm.nih.gov/27450736/)
